Lenzetto (Estradiol Hemihydrate)

Estradiol hemihydrate binds to estrogen receptors ERα and ERβ in various tissues. This binding triggers transcription of estrogen‑responsive genes, restoring estrogenic activity that controls temperature regulation, supports bone remodeling, and maintains the health of urogenital tissues.

The specific dose and patch change interval for Lenzetto are determined by the prescribing clinician based on the individual’s therapeutic needs, health status, and response to treatment. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Lenzetto is contraindicated in pregnancy because estrogen exposure can affect fetal development. It is also generally not recommended while breastfeeding, as estradiol can pass into breast milk and potentially affect the infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenzetto delivers estradiol through the skin, providing more stable plasma concentrations and avoiding first‑pass metabolism that occurs with oral tablets. This can reduce gastrointestinal side effects and may offer better control of hormone levels, though individual response varies and the choice depends on patient preference and clinical considerations.

Store Lenzetto patches at room temperature, below 25 °C, in their original sealed packaging. Protect them from moisture, direct sunlight and extreme temperatures. Do not expose the patch to heat sources or store it in a bathroom where humidity is high.

The patch is applied to clean, dry, hair‑free skin on the lower abdomen or buttock. Press firmly for several seconds to ensure good contact, then replace it according to the prescriber’s schedule, typically every 3–4 days. Rotate application sites to minimize skin irritation.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe reactions can involve gallbladder disease and severe allergic responses. Patients should promptly report any sudden leg swelling, chest pain, shortness of breath, or signs of an allergic reaction.

Lenzetto should not be used by women with a history of estrogen‑dependent cancers (e.g., breast or endometrial cancer), active or past thromboembolic disease, uncontrolled hypertension, liver disease, or known hypersensitivity to estradiol or patch components. It is also contraindicated during pregnancy.